Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep demonstrates 69% ORR in pancreatic cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 21, 2023 5:01pm

102 Views

Post# 35694833

RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancer

So what does the expansion of new and pre-existing T-cell clones with the oncolytic virus pelareorep mean? Well, T cells are a type of white blood cell that play a crucial role in the immune system. T-cell clones are groups of T cells that have the same antigen receptor, which allows them to recognize and respond to specific antigens. The expansion of new and pre-existing T-cell clones refers to the proliferation of these T-cell clones in response to an antigen or other stimulus. When T cells encounter an antigen or an OV like pelareorep, they undergo clonal expansion, which means that they divide and differentiate into effector cells that can eliminate the antigen. This process is important for the immune system to mount an effective response against pathogens or cancer cells . The expansion of pre-existing T-cell clones can also occur in response to immunotherapy, such as checkpoint inhibitors or CAR-T cells, which can activate and enhance the function of T cells against cancer cells

<< Previous

Bullboard Posts

Next >>

New glaucoma treatment studied in a $3.4 billion market